CCN2 and open-angle glaucoma: Work by our laboratory has shown that a humanized monoclonal anti-CTGF antibody FG-3019 was able to effectively block ECM production as shown by a significant reduction in the expression of profibrotic genes[33], in LC and TM cells treated with AH samples from pseudoexfoliation glaucoma (PXFG), primary open angle glaucoma (POAG), and hydrogen peroxide.